873 related articles for article (PubMed ID: 25556849)
1. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
2. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
3. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
[TBL] [Abstract][Full Text] [Related]
4. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
[TBL] [Abstract][Full Text] [Related]
5. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
[TBL] [Abstract][Full Text] [Related]
6. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
7. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
[TBL] [Abstract][Full Text] [Related]
8. First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease.
Mariano M; Schmitt C; Miralinaghi P; Catto M; Hartmann RW; Carotti A; Engel M
ACS Chem Neurosci; 2014 Dec; 5(12):1198-202. PubMed ID: 25247807
[TBL] [Abstract][Full Text] [Related]
9. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
10. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
11. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice.
Velazquez R; Meechoovet B; Ow A; Foley C; Shaw A; Smith B; Oddo S; Hulme C; Dunckley T
Mol Neurobiol; 2019 Dec; 56(12):8364-8375. PubMed ID: 31240602
[TBL] [Abstract][Full Text] [Related]
12. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
13. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
[TBL] [Abstract][Full Text] [Related]
14. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Pathak A; Rohilla A; Gupta T; Akhtar MJ; Haider MR; Sharma K; Haider K; Yar MS
Eur J Med Chem; 2018 Oct; 158():559-592. PubMed ID: 30243157
[TBL] [Abstract][Full Text] [Related]
15. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
[TBL] [Abstract][Full Text] [Related]
16. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression.
Qian W; Jin N; Shi J; Yin X; Jin X; Wang S; Cao M; Iqbal K; Gong CX; Liu F
J Alzheimers Dis; 2013; 37(3):529-38. PubMed ID: 23948904
[TBL] [Abstract][Full Text] [Related]
17. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
[TBL] [Abstract][Full Text] [Related]
18. Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7.
Chu D; Lei L; Gu S; Liu F; Wu F
Biochem Pharmacol; 2024 Jun; 224():116233. PubMed ID: 38663682
[TBL] [Abstract][Full Text] [Related]
19. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
[TBL] [Abstract][Full Text] [Related]
20. DYRK1A inhibition as potential treatment for Alzheimer's disease.
Stotani S; Giordanetto F; Medda F
Future Med Chem; 2016 Apr; 8(6):681-96. PubMed ID: 27073990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]